This is genuinely unresolved, and it is one of the sharpest disagreements in the research.
Some studies, including a small randomized-origin imaging study, suggest women who carry the APOE4 gene variant may get the most brain benefit from hormone therapy. Other, newer studies looking at spinal fluid markers found APOE4 carriers who used hormone therapy had worse Alzheimer's-related biomarkers than other women, with earlier starting age making it worse rather than better in carriers specifically. No guideline recommends genetic testing to make this decision, because the evidence points in both directions and the studies are small.
This is the most bidirectional evidence conflict in the whole topic: a small randomized imaging study points toward benefit in carriers, while a newer observational spinal-fluid study points toward harm in carriers, and both are small studies.
What the research shows, and which source each finding rests on
A small randomized-origin imaging substudy found transdermal estradiol was associated with lower amyloid PET burden specifically in APOE4 carriers three years after treatment ended.
A separate observational cohort found APOE4-carrying hormone therapy users had worse spinal fluid Alzheimer's biomarker ratios than other women, with younger age at hormone start associated with worse ratios in carriers only.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
APOE4 carriers benefit most from hormone therapy
researchers behind the KEEPS imaging substudy and a separate observational brain-volume study
In one pilot imaging study, transdermal estradiol was linked to markedly lower amyloid PET burden in carriers, and an observational cohort found carriers on hormone therapy had the highest delayed-memory scores and larger entorhinal and amygdala brain volumes.
APOE4 carriers may be harmed or at higher pathological risk
the Wisconsin cohort researchers behind the newer spinal fluid study
In their observational sample of women with elevated familial Alzheimer's risk, APOE4-carrying hormone therapy users had worse spinal fluid ratios than everyone else, and starting younger made the ratios worse in carriers only, the opposite of what the timing hypothesis would predict.
What would settle it: An adequately powered randomized trial stratified by APOE genotype with biomarker endpoints; researchers behind the observational brain-volume study have explicitly called for prospective recruitment by genotype.
What is really going on here
- Should I get an APOE test before deciding on hormone therapy?
- Is the evidence I'm hearing about my gene status from a randomized trial or an observational study?
Questions for your doctor
- Do you recommend genetic testing before making this decision, and why or why not?
- If I have a family history of Alzheimer's, does that change your recommendation regardless of genotype?
- What would you tell me if the evidence on my specific situation is genuinely mixed?
Questions with no answer yet
Does hormone therapy help or harm the brains of women who carry the APOE4 gene variant?
Partly studiedWhat is known: A small randomized-origin imaging study found lower amyloid buildup in APOE4 carriers on transdermal estradiol, while a separate observational cohort using spinal fluid markers found APOE4-carrying users had worse Alzheimer's-related biomarker ratios, with earlier starting age making it worse rather than better in carriers specifically. Both findings come from small studies pointing in opposite directions.
What would test it: An adequately powered randomized trial stratified by APOE genotype from the start, with biomarker endpoints, which researchers behind the observational findings have explicitly called for.
Is there a biological reason a woman's genotype would flip the direction of hormone therapy's effect on her brain, or are these two small studies simply too different in design and population to compare directly?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: One study was a randomized-origin pilot with imaging outcomes; the other was observational, in a cohort with elevated familial Alzheimer's risk, using spinal fluid rather than imaging. No study has been designed to directly reconcile the two using the same population and the same outcome measure.
What would test it: A single trial or cohort measuring both imaging and fluid biomarkers in the same APOE-stratified group of women, to see whether the two measurement approaches agree.
Sources
- 1.Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.Kantarci K et al. (KEEPS imaging), J Alzheimers Dis 2016 · Comparative or small study
- 2.Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4-carrying women: An observational study.Jauregi-Zinkunegi A et al., Alzheimers Dement 2025 · Observational study
- 3.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 Hormone Therapy Position Statement of The North American Menopause Society, Menopause 2022 · Systematic review or guideline
- 4.Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort.Saleh RNM et al. (EPAD cohort), Alzheimers Res Ther 2023 · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Can taking hormone therapy prevent Alzheimer's disease or dementia?
- Is it true that hormone therapy doubles your risk of dementia?
- Does it matter how soon after menopause I start hormone therapy, for my brain?
- Does having early menopause or having my ovaries removed increase my risk of dementia?
- I read a study that said hormone therapy causes dementia, even in women who started young. Is that true?
- Does the type of hormone therapy matter for dementia risk, or is it all the same?
- Back to topic: Hormone therapy and the brain